Ventyx is a clinical-stage biopharmaceutical company developing oral therapies that selectively modulate key immune targets, including NLRP3, S1P1R, and TYK2, for patients with autoimmune and inflammatory disorders. The company aims to transition treatment from injectables to oral medications, addressing the need for more convenient and accessible therapeutic options in this patient population.
Funding
$27M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients with autoimmune and inflammatory disorders rely on injectable medications, which can be inconvenient and less accessible compared to oral treatments. This creates a need for more convenient and patient-friendly therapeutic options.
Solution
Ventyx Biosciences is developing a pipeline of oral therapies designed to selectively modulate key immune targets, such as NLRP3, S1P1R, and TYK2. By focusing on oral medications, Ventyx aims to provide patients with more convenient and accessible treatment options for autoimmune and inflammatory conditions. Their approach seeks to shift the immunology market from injectables to oral drugs, addressing unmet medical needs with differentiated drug candidates. The company's pipeline includes multiple clinical-stage programs.
Target Audience
The primary target audience is patients living with autoimmune and inflammatory disorders who require convenient and accessible treatment options.
Features
- Development of oral therapies targeting NLRP3, S1P1R, and TYK2.
- Focus on selective modulation of key immune targets.
- Clinical-stage programs advancing through development.
- Aims to replace injectable medications with oral alternatives.